Other Events ·
Clearmind completes patient recruitment for first Alcohol Use Disorder cohort in its CMND-100 Phase I/IIa clinical trial
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced the completion of patient recruitment for Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD). This segment marks the company's first clinical evaluation of the drug in AUD patients, following the successful completion of Part A in healthy volunteers. The trial involves two sequential single-dose ascending cohorts of six patients each, assessing safety, tolerability, pharmacokinetics, and early efficacy signals. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders.